BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Marlotamig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Marlotamig\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07058012-2176@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20290417
DTEND;VALUE=DATE:20290418
SUMMARY:Marlotamig: Phase 2 readout est. (NCT07058012)
DESCRIPTION:Marlotamig\, phase 2.\nStudy: A Phase II Platform Study to Eval
 uate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or
  Other Novel Combinations in Patients With Colorectal Cancer With Minimal 
 Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)\nE
 stimated primary completion: 17 April 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/marlotamig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07058012
URL:https://assetmemo.bio/drug/marlotamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465329-2176@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20291204
DTEND;VALUE=DATE:20291205
SUMMARY:Marlotamig: Phase 2 readout est. (NCT06465329)
DESCRIPTION:Marlotamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Pl
 us Other Cancer Treatments for Adult Patients With Operable Non-Small Cell
  Lung Cancer (NSCLC)\nEstimated primary completion: 4 December 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/marlotamig#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06465329
URL:https://assetmemo.bio/drug/marlotamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154290-2176@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20300610
DTEND;VALUE=DATE:20300611
SUMMARY:Marlotamig: Phase 2 readout est. (NCT07154290)
DESCRIPTION:Marlotamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Ad
 ult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCL
 C)\nEstimated primary completion: 10 June 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/marlotamig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07154290
URL:https://assetmemo.bio/drug/marlotamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281768-2176@assetmemo.bio
DTSTAMP:20261121T005656Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Marlotamig: Phase 2 readout est. (NCT07281768)
DESCRIPTION:Marlotamig\, phase 2.\nStudy: Capecitabine/Oxaliplatin Chemothe
 rapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advan
 ced Rectal Cancer\nEstimated primary completion: July 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/marlotamig#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07281768
URL:https://assetmemo.bio/drug/marlotamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
